Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
To evaluate nonclassic AME (NC-AME) due to partial 11β-HSD2 insufficiency and its association with hypertension, mineralocorticoid receptor (MR) activation, and inflammatory parameters.
|
30239803 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Serum F/E ratio and cortisone allow to identify partial 11βHSD2 deficiencies, as occurs in heterozygous subjects, who would be susceptible to develop arterial hypertension.
|
29617893 |
2018 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Impaired 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2)-dependent cortisol inactivation can lead to electrolyte dysbalance, hypertension and cardiometabolic disease.
|
28131847 |
2017 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Licorice root, whose active ingredient, glycerrhetinic acid (GA), inhibits renal 11β-HSD2, and thereby causes hypertension in some individuals.
|
28624548 |
2017 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Our data suggest that kidney-specific deficiency of 11β-HSD2 leads to salt-dependent hypertension, which is attributed to mineralocorticoid receptor-epithelial sodium channel-Na<sup>+</sup>-Cl<sup>-</sup> cotransporter activation in the kidney, and provides evidence that renal dysfunction is essential for developing the phenotype of apparent mineralocorticoid excess.
|
28559392 |
2017 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The deactivation of glucocorticoid by 11βHSD2 controls ligand access to glucocorticoid and mineralocorticoid receptors: loss of function promotes salt retention and hypertension.
|
29138984 |
2017 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
The current study was conducted to determine if reduced 11β-HSD2 activity is also associated with having resistant HTN.
|
28180242 |
2017 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Furthermore, polymorphisms in the 11β-HSD2 coding gene (HSD11B2) have been linked to high blood pressure and salt sensitivity, major cardiovascular risk factors.
|
28938454 |
2017 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Apparent mineralocorticoid excess (AME) is a rare autosomal recessive genetic disorder causing severe hypertension in childhood due to a deficiency of 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2), which is encoded by HSD11B2.
|
27526338 |
2016 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
However, the serum F/E ratio was associated with BP, suggesting a role of 11βHSD2 in mineralocorticoid hypertension.
|
25907225 |
2016 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The hypertension phenotype is also epigenetically modulated by HSD11B2 methylation in subjects heterozygous for the mutation.
|
26126204 |
2015 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Post-translational histone methylation at different histone 3 lysine residues was also observed to control the expression of genes related to AH as lysine-specific demethylase-1(LSD1), HSD11B2, and epithelial sodium channel subunit α (SCNN1A).
|
25035152 |
2015 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
The isozyme 11beta-HSD2 is selectively expressed in mineralocorticoid target tissues and its activity is reduced in various disease states with abnormal sodium retention and hypertension, including the apparent mineralocorticoid excess.
|
25133511 |
2014 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
To gain insight into potentially relevant miRNAs in vivo, we investigated 2 models with differential 11β-HSD2 activity linked with salt-sensitive hypertension.
|
24980668 |
2014 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Genotyping indicated no hypertension related mutations in the coding region and short introns of HSD11B2.
|
23303402 |
2013 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
It has been reported that the G534A(Glu178/Glu) polymorphism in the HSD11B2 gene is associated with hypertension.
|
22278213 |
2012 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
These findings indicate that variants of the HSD11B2 gene may contribute to the enhanced blood pressure response to salt and possibly to hypertension in humans.
|
19909806 |
2010 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
In conclusion, 19-nor-P did not inhibit human 11beta-HSD2 and seems not to be involved in human hypertension.
|
19811365 |
2009 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The enhanced cortisol levels are backed by recent genetic findings on HSD11B2 polymorphisms and may promote hypertension.
|
18337758 |
2008 |
Hypertensive disease
|
0.700 |
PosttranslationalModification
|
group |
LHGDN |
These results show a clear link between the epigenetic regulation through repression of HSD11B2 in PBMC DNA and hypertension.
|
18178212 |
2008 |
Hypertensive disease
|
0.700 |
PosttranslationalModification
|
group |
BEFREE |
These results show a clear link between the epigenetic regulation through repression of HSD11B2 in PBMC DNA and hypertension.
|
18178212 |
2008 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Therefore, impaired 11beta-HSD2 protein stability rather than reduced gene expression or loss of catalytic activity seems to be responsible for the development of hypertension in some individuals with AME.
|
17314322 |
2007 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Epidemiological data suggests that polymorphic variability in the HSD11B2 gene determines salt sensitivity in the general population, which is a key predisposing factor to adult onset hypertension in some patients.
|
16980198 |
2006 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
LHGDN |
In AME, defective HSD11B2 enzyme activity results in overstimulation of the mineralocorticoid receptor (MR) by cortisol, causing sodium retention, hypokalemia, and salt-dependent hypertension.
|
16778331 |
2006 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Impaired 11beta-HSD2 activity has been suggested in patients with hypertension as well as in patients with renal disease, where it may contribute to sodium retention, oedema and hypertension.
|
16061836 |
2005 |